Kamata Tomihisa
External Director @ Axelspace Holdings
Tokyo, Japan
Kamata Tomihisa is a seed investor at Axelspace Holdings in Tokyo focused on Fitness and Medical. Dr. Kamada earned his Ph.D. at the University of Tokyo. In 1984, he pursued his journey to establish his own business that focused on information appliances and mobile software, namely ACCESS Co., Ltd.. With great success, the company entered the Tokyo Stock Exchange Mothers Market in 2001. He left ACCESS Co., Ltd. in 2011, and founded TomyK Ltd.in 2012 where he supports startups possessing revolutionary business ideas that revitalize the Japanese economy.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Kamata Tomihisa invests in
Stages Kamata Tomihisa invests in
Countries Kamata Tomihisa invests in
Investment Focus
Industry
- Fitness 1 (33%)
- Medical 1 (33%)
- Genetics 1 (33%)
- Wellness 1 (33%)
- Health Care 1 (33%)
Stage
- Seed 2 (67%)
- Angel 1 (33%)
Country
- Japan 2 (67%)
- United States 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SmarTrial
|
Activaid owns and operates a social data platform for patients with inflammatory bowel disease. It allows patients to support and exchange information within the patient community with the same disease; provide information necessary for new drug development and matching to clinical trials that suits them; and improve medical treatment. YasuakiHasebe founded Activaid in 2018. It has its headquarters in Tokyo in Japan. | Angel / Jun 13, 2019 | |
MinD in a Device
|
MinD in a Device Co., Ltd. is a university-launched venture that aims to port human consciousness to devices (machines and computers) in the medium to long term based on long-term research results on consciousness. As the first step toward realization, we will evolve and deepen the "generation model" considered to be the source ofconsciousness, and promote the development of next-generation AI and social implementation. | Seed / Mar 25, 2019 | |
Genomelink
|
Genomelink is a platform where people discover more with their DNA data and help businesses build, market and do research with it. The best founders in consumer genomics with real experience in the industry for many years, including M3, Inc. ($13B valued Meditech in Japan), a founding member of the Japanese version of 23andMe, and leadbioinformatician and software engineer at a joint-venture between Illumina and Sony. Raised $4M for Seed Round from Berkeley SkyDeck, SONY, and top-tier Japanese VCs. Supported by Illumina Accelerator, Carlos Bustamante Lab at Stanford University among others. | $7.1M / Seed / Aug 22, 2017 |
Co-Investors
About Axelspace Holdings
Axelspace is a startup company developing businesses in the microsatellite field. Axelspace plans to construct a monitoring platform to cover the entire globe on a daily basis at extremely low cost.
Axelspace Holdings Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Kamata Tomihisa
External Director
|
|||
Masaru Murai
Auditor
|
|||
Naoki Miyashita
Director & CTO
|
|||
|
Takashi Eishima
Senior Fellow
|
|||
|
Yasunori Yamazaki
CBO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Kamata Tomihisa invest in?
Kamata Tomihisa invests primarily in Fitness, Medical and Genetics startups, most often at Seed and Angel stage. Most of the 3 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Kamata Tomihisa last invest?
The most recent investment recorded for Kamata Tomihisa closed in Jun 2019. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
